STOCK TITAN

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) announced the acceptance of two Trials in Progress abstracts for ASPEN-03 and ASPEN-04, Phase 2 studies on advanced head and neck cancer, at the SITC 37th Annual Meeting in Boston from November 8-12, 2022. The abstracts detail studies on evorpacept (ALX148) combined with pembrolizumab, with session times on November 10-11, 2022. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with evorpacept showing promising results for various cancers.

Positive
  • Acceptance of two Trials in Progress abstracts indicates recognition by the scientific community.
  • Presentation of promising data on evorpacept may attract investor interest.
  • Collaboration with Merck strengthens the credibility of the trials.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the acceptance of two Trials in Progress abstracts related to ASPEN-03 and ASPEN-04, the Company’s Phase 2 head and neck cancer studies in collaboration with Merck (known as MSD outside the US and Canada), at the SITC 37th Annual Meeting in Boston, MA, from November 8–12, 2022.

Poster Presentation Details

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03
Abstract Number: 678
Session Date and Time: November 10-11, 2022, from 9:00 am – 9:00 pm ET
Location: Poster Hall

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04
Abstract Number: 676
Session Date and Time: November 10-11, 2022, from 9:00 am – 9:00 pm ET
Location: Poster Hall

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.


FAQ

What are the recent developments for ALXO regarding cancer studies?

ALX Oncology announced the acceptance of two abstracts for ASPEN-03 and ASPEN-04 at the SITC 37th Annual Meeting.

When will ALX Oncology present its cancer studies?

The studies will be presented on November 10-11, 2022.

What is the focus of ALX Oncology's research?

The company focuses on therapies that block the CD47 checkpoint pathway in cancer treatment.

What is evorpacept?

Evorpacept (ALX148) is a CD47 blocking therapeutic developed by ALX Oncology.

ALX Oncology Holdings Inc.

NASDAQ:ALXO

ALXO Rankings

ALXO Latest News

ALXO Stock Data

81.22M
41.97M
1.97%
88.23%
13.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO